PMID- 36112505
OWN - NLM
STAT- MEDLINE
DCOM- 20221012
LR  - 20231105
IS  - 1479-6813 (Electronic)
IS  - 0952-5041 (Linking)
VI  - 69
IP  - 4
DP  - 2022 Nov 1
TI  - How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
PG  - T69-T83
LID - 10.1530/JME-22-0141 [doi]
AB  - Acute promyelocytic leukemia (APL) is associated with severe coagulopathy leading 
      to rapid morbidity and mortality if left untreated. The definitive diagnosis of 
      APL is made by identifying a balanced reciprocal translocation between 
      chromosomes 15 and 17. This t(15;17) results in a fusion transcript of 
      promyelocytic leukemia (PML) and retinoic acid receptor alpha (RARA) genes and 
      the expression of a functional PML/RARA protein. Detection of a fused PML/RARA 
      genomic DNA sequence using fluorescence in situ hybridization (FISH) or by 
      detection of the PML/RARA fusion transcript via reverse transcriptase polymerase 
      chain reaction (RT-PCR) has revolutionized the diagnosis and monitoring of APL. 
      Once confirmed, APL is cured in over 90% of cases, making it the most curable 
      subtype of acute leukemia today. Patients with low-risk APL are successfully 
      treated using a chemotherapy-free combination of all-trans retinoic acid and 
      arsenic trioxide (ATO). In this review, we explore the work that has gone into 
      the modern-day diagnosis and highly successful treatment of this once devastating 
      leukemia.
FAU - Korsos, Victoria
AU  - Korsos V
AUID- ORCID: 0000-0002-5255-5513
AD  - Division of Hematology, Jewish General Hospital, Montreal, Canada.
AD  - Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, 
      Canada.
FAU - Miller, Wilson H Jr
AU  - Miller WH Jr
AUID- ORCID: 0000-0002-7408-1574
AD  - Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, 
      Canada.
AD  - Gerald Bronfman Department of Oncology, Jewish General Hospital, Montreal, 
      Canada.
AD  - Lady Davis Institute for Medical Research, Montreal, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221011
PL  - England
TA  - J Mol Endocrinol
JT  - Journal of molecular endocrinology
JID - 8902617
RN  - 0 (Nuclear Proteins)
RN  - 0 (Promyelocytic Leukemia Protein)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoic Acid Receptor alpha)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 5688UTC01R (Tretinoin)
RN  - N712M78A8G (Arsenic)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - *Arsenic
MH  - Arsenic Trioxide/therapeutic use
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Leukemia, Promyelocytic, Acute/diagnosis/drug therapy/genetics
MH  - Nuclear Proteins/genetics
MH  - Promyelocytic Leukemia Protein/genetics
MH  - Receptors, Retinoic Acid/genetics
MH  - Retinoic Acid Receptor alpha/genetics
MH  - Transcription Factors/metabolism
MH  - Translocation, Genetic
MH  - Tretinoin/therapeutic use
MH  - Tumor Suppressor Proteins/genetics/metabolism
OTO - NOTNLM
OT  - oncology
OT  - receptors
OT  - retinoic acid
OT  - transcription
EDAT- 2022/09/17 06:00
MHDA- 2022/10/13 06:00
CRDT- 2022/09/16 12:43
PHST- 2022/09/14 00:00 [received]
PHST- 2022/09/16 00:00 [accepted]
PHST- 2022/09/17 06:00 [pubmed]
PHST- 2022/10/13 06:00 [medline]
PHST- 2022/09/16 12:43 [entrez]
AID - 10.1530/JME-22-0141 [doi]
PST - epublish
SO  - J Mol Endocrinol. 2022 Oct 11;69(4):T69-T83. doi: 10.1530/JME-22-0141. Print 2022 
      Nov 1.